BRAF-mutated metastatic colorectal cancer between past and future

British Journal of Cancer

Volumn 113, Issue 11, 2015, Pages 1634-1635

  Cremolini, Chiara ^a   Di Maio, Massimo ^b   Petrelli, Fausto ^c   Berenato, Rosa ^d   Loupakis, Fotios ^a   Pietrantonio, Filippo ^d  

^a UNIVERSITY HOSPITAL OF PISA   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

^c TREVIGLIO HOSPITAL   (Italy)

^d NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; BEVACIZUMAB; CETUXIMAB; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY EGFR; UNCLASSIFIED DRUG; EPIDERMAL GROWTH FACTOR RECEPTOR;

CANCER CHEMOTHERAPY; CANCER PATIENT; CLINICAL TRIAL (TOPIC); GENE MUTATION; HUMAN; LETTER; META ANALYSIS (TOPIC); METASTATIC COLORECTAL CANCER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); ANTAGONISTS AND INHIBITORS; COLORECTAL NEOPLASMS; GENETICS; MUTATION;

COLORECTAL NEOPLASMS; HUMANS; MUTATION; PROTO-ONCOGENE PROTEINS B-RAF; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84949321830     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2015.316     Document Type: Letter

References (10)

1. Afghahi A, Mathur M, Seto T, Desai M, Kenkare P, Horst KC, Das AK, Thompson CA, Luft HS, Yu PP, Gomez SL, Low Y, Shah NH, Kurian AW, Sledge GW. (2015). Lymphopenia after radiotherapy (RT) to predict poor survival in triplenegative breast cancer (TNBC). J Clin Oncol 33(Suppl): 1069.
2. Balmanoukian A, Ye X, Herman J, Laheru D, Grossman SA. (2012). The association between treatment-related lymphopenia and survival in newly diagnosed patients with resected adenocarcinoma of the pancreas. Cancer Invest 30(8): 571-576.
3. Campian JL, Ye X, Brock M, Grossman SA. (2013). Treatment-related lymphopenia in patients with stage III non-small-cell lung cancer. Cancer Invest 31(3): 183-188.
4. Ellsworth S, Balmanoukian A, Kos F, Nirschl C, Nirschl T, Grossman S, Luznik L, Drake CG. (2014). Sustained CD4+ cell driven lymphopenia without a compensatory IL7/Il15 response among high-grade glioma patients treated with radiation and temozolomide. Oncoimmunology 3(1): e27357.
5. Grossman SA, Ye X, Lesser G, Sloan A, Carraway H, Desideri S, Piantadosi S. NABTT CNS Consortium. (2011). Immunosuppression in patients with highgrade gliomas treated with radiation and temozolomide. Clin Cancer Res 17(16): 5473-5480.
6. MacLennan IC, Kay HE. (1978). Analysis of treatment in childhood leukemia. IV. The critical association between dose fractionation and immunosuppression induced by cranial irradiation. Cancer 41(1): 108-111.
7. Tang C, Liao Z, Gomez D, Levy L, Zhuang Y, Gebremichael RA, Hong DS, Komaki R, Welsh JW. (2014). Lymphopenia association with gross tumor volume and lung V5 and its effects on non-small cell lung cancer patient outcomes. Int J Radiat Oncol Biol Phys 89(5): 1084-1091.
8. Wild AT, Ye X, Ellsworth SG, Smith JA, Narang AK, Garg T, Campian J, Laheru DA, Zheng L, Wolfgang CL, Tran PT, Grossman SA, Herman JM. (2013). The association between chemoradiation-related lymphopenia and clinical outcomes in patients with locally advanced pancreatic adenocarcinoma. Am J Clin Oncol 38(3): 259-265.
9. Wong ET, Lok E, Gautam S, Swanson KD. (2015). Dexamethasone exerts profound immunologic interference on treatment efficacy for glioblastoma. Br J Cancer 113(2): 232-241.
10. Yovino S, Kleinberg LR, Grossman SA, Narayanan M, Ford E. (2013). The Etiology of treatment-related lymphopenia in patients with malignant gliomas: modeling radiation dose to circulating lymphocytes explains clinical observations and suggests methods of modifying the impact of radiation on immune Cells. Cancer Invest 31(2): 140-144.